欧普康视(300595) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 401,473,749.24, representing an increase of 8.17% compared to the same period last year[3]. - Net profit attributable to shareholders for Q1 2023 was CNY 173,217,878.06, up 16.96% year-on-year[3]. - The net profit excluding non-recurring gains and losses was CNY 149,290,819.27, reflecting an increase of 8.43% compared to the previous year[3]. - The total operating revenue for Q1 2023 was CNY 401,473,749.24, an increase of 8.4% compared to CNY 371,150,930.09 in Q1 2022[26]. - The total profit for Q1 2023 was approximately ¥230.45 million, an increase from ¥185.84 million in Q1 2022, representing a growth of about 24%[28]. - The net profit for Q1 2023 reached approximately ¥197.64 million, compared to ¥163.41 million in the same period last year, marking an increase of around 21%[28]. - Basic earnings per share for Q1 2023 were ¥0.1940, up from ¥0.1744 in Q1 2022, reflecting a growth of approximately 11%[29]. - The company's total comprehensive income for Q1 2023 was approximately ¥197.64 million, compared to ¥163.41 million in Q1 2022, showing an increase of around 21%[28]. - The net profit attributable to the parent company for Q1 2023 was approximately ¥173.22 million, up from ¥148.10 million in Q1 2022, indicating a growth of about 17%[28]. Cash Flow and Financing - The net cash flow from operating activities was CNY 192,191,357.35, which is a 21.07% increase from the same period last year[3]. - Cash flow from operating activities for Q1 2023 was approximately ¥192.19 million, compared to ¥158.75 million in Q1 2022, indicating an increase of about 21%[31]. - Total cash inflow from financing activities decreased by 90.87% to ¥4,676,000.00, primarily due to the absence of equity incentive plan investment funds received in the same period last year[16]. - Total cash outflow from financing activities decreased by 31.17% to ¥23,538,056.86, mainly due to reduced lease payments and dividends paid to minority shareholders[16]. - Net cash flow from financing activities turned negative at -¥18,862,056.86, a decline of 210.84% compared to the previous year, attributed to the lack of equity incentive plan investment funds[16]. - The net cash flow from financing activities for Q1 2023 was approximately -¥18.86 million, compared to ¥17.02 million in Q1 2022, indicating a significant change in financing strategy[32]. Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 5,382,768,238.63, marking a 5.16% increase from the end of the previous year[3]. - Total current assets rose to ¥3,885,653,429.76, up from ¥3,769,238,489.78, indicating an increase of about 3.1%[23]. - Long-term equity investments increased to ¥451,820,701.87 from ¥381,460,072.17, representing a growth of approximately 18.4%[23]. - The company's total liabilities amounted to CNY 574,839,914.04, up from CNY 523,048,227.89, reflecting a rise of 9.9%[25]. - The equity attributable to shareholders increased to CNY 4,404,629,254.26 from CNY 4,230,206,261.41, showing a growth of 4.1%[25]. Operational Efficiency - The total operating costs decreased to CNY 194,230,834.44 from CNY 196,126,226.70, reflecting a reduction of 1% year-over-year[27]. - Operating profit for Q1 2023 was CNY 231,054,020.43, up from CNY 185,693,212.41 in the same period last year, representing a growth of 24.5%[27]. - The company reported a net profit margin improvement, with net profit increasing significantly due to higher operating efficiency[27]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 67,979, with the top ten shareholders holding a combined 56.27% of shares[18]. - Tao Yuequn, a natural person, holds 33.40% of shares, amounting to 298,890,828 shares[18]. Future Outlook - The company expects the trend of order growth to continue into Q2 2023 as business operations return to normal[8]. - Future outlook includes plans for market expansion and potential new product launches to drive further revenue growth[27]. Research and Development - Research and development expenses for Q1 2023 were CNY 7,861,038.77, slightly down from CNY 8,887,583.69 in Q1 2022[27]. - The company has not disclosed any new product or technology developments in the current report[21]. - There are no significant mergers or acquisitions reported during this period[21].